Background and purpose: Cerebrovascular smooth muscle cells express the CB 1 cannabinoid receptor and CB 1 agonists produce vasodilatation of the middle cerebral artery (MCA). The thromboxane A 2 mimetic, U-46619, increased the content of the endocannabinoid, 2-arachidonoylglycerol (2-AG) in the MCA and 2-AG moderated the vasoconstriction produced by U46619 in this tissue. The purposes of this study were to examine the extent to which 2-AG is catabolized by cerebral arteries and to determine whether blockade of 2-AG inactivation potentiates its feedback inhibition of U-44619-mediated vasoconstriction. Experimental approach: The diameters of isolated, perfused MCA from male rats were measured using videomicroscopy. Key results: Exogenous 2-AG produces a CB 1 receptor-dependent and concentration-related increase in the diameter of MCA constricted with 5-HT. The E max for 2-AG dilation is increased 4-fold in the presence of the metabolic inhibitors 3-(decylthio)-1,1,1-trifluropropan-2-one (DETFP), URB754 and URB597. To examine the role of catabolism in the effects of endogenous 2-AG, vasoconstriction induced by U-46619 was studied. DETFP and URB754, but not the fatty acid amide hydrolase inhibitor, URB597, significantly increased the EC 50 for U-46619. These data support a physiological role for endocannabinoid feedback inhibition in the effects of U-46619 and indicate that endogenously produced 2-AG is also efficiently catabolized within the MCA. Conclusions and implications: MCA express mechanisms for the efficient inactivation of 2-AG, providing further support for an endocannabinoid feedback mechanism that opposes thromboxane-mediated vasoconstriction. These data suggest that potentiation of endogenously produced 2-AG could be a novel therapeutic approach to the treatment of thrombotic stroke.
Introduction
Cannabinoids exert significant effects on the cardiovascular system through a variety of mechanisms (Hillard, 2000b; Pacher et al., 2005) . In fact, the most common physiological consequences of marijuana intoxication in humans are cardiovascular in nature (Dewey, 1986) . Exposure to cannabinoids via smoking marijuana and oral administration of synthetic and plant extracted compounds results in a spectrum of cardiovascular changes that include tachycardia and orthostatic hypotension that can be accompanied by significant dizziness and syncope upon standing (Mathew et al., 2003) .
A variety of studies reveal that cannabinoids exert significant effects on the cerebral circulation. Humans exposed to marijuana exhibit a significant drop in cerebral blood velocity upon standing that is consistent with a loss of cerebral autoregulation (Mathew et al., 1992a (Mathew et al., , b, 2003 Mathew and Wilson, 1993) . Preclinical studies have shown that cerebral arterial vascular smooth muscle cells from cat and rat express the CB 1 cannabinoid receptor protein (Gebremedhin et al., 1999; Ashton et al., 2004; Rademacher et al., 2005) . Electrophysiological studies demonstrate that the CB 1 receptor agonist, Win 55212-2, produces potent and nearly complete inhibition of the opening of L-type calcium channels of isolated cat arteriolar vascular smooth muscle cell (Gebremedhin et al., 1999) . The EC 50 for this effect of Win 55212-2 is approximately 30 nM and it is blocked by both Pertussis toxin and the CB 1 receptor antagonist, rimonabant (also called SR141716). Therefore, cerebral vascular smooth muscle cells express a CB 1 receptor that couples to the inhibition of L-type calcium channel opening via a Pertussis toxin-sensitive G protein. Most probably, as a result of this signalling mechanism, agonists of the CB 1 cannabinoid receptor produce vasodilatation of cerebral resistance vessels at nanomolar concentrations (Ellis et al., 1995; Gebremedhin et al., 1999; Wagner et al., 2001; Rademacher et al., 2005) .
Among the questions that arise from these studies is 'What is the role and nature of endogenous CB 1 receptor signalling in the cerebral vasculature?'. Regulation of vascular tone is accomplished through the actions of constricting and dilating factors that arise from a variety of cellular sources, and we hypothesize that the endocannabinoids are one of these physiological regulators of cerebrovascular tone. There is considerable evidence that two arachidonic acid derivatives, N-arachidonoylethanolamine (AEA or anandamide) and 2-arachidonoylglycerol (2-AG) function as endogenous agonists of CB 1 cannabinoid receptors. Both of these molecules are present in lipid extracts of rat middle cerebral artery (MCA) . Recent work from our laboratory suggests that endocannabinoid signalling in the MCA functions as a feedback mechanism that opposes vasoconstriction produced by thromboxane A 2 . In particular, we have shown that nanomolar concentrations of the thromboxane mimetic, U-46619, produces significant increases in the content of both AEA and 2-AG, in the MCA . Moreover, inhibition of CB 1 receptor activation results in increased U-46619-mediated vasoconstriction. These data are consistent with the hypothesis that thromboxane receptor activation results in both vasoconstriction and in the synthesis of vasodilatory endocannabinoids, and that the endocannabinoids act via the CB 1 receptor to oppose or moderate the vasoconstriction produced by U-46619.
In the present study, we have postulated that if endocannabinoid signalling is physiologically important in the cerebrovasculature, then mechanisms involved in endocannabinoid inactivation should be present and functional. We have carried out two studies to explore this hypothesis: first, we have determined the effects of known inhibitors of 2-AG catabolism on the vasodilatory efficacy of exogenously added 2-AG; and, second, we have determined the effects of these inhibitors on the constrictor response to U-46619. The feedback hypothesis presented above predicts that potentiation of endogenously produced 2-AG (through inhibition of 2-AG catabolism) will reduce the vasoconstriction produced by U-46619.
Methods

Animals
All experimental protocols were approved by the Institutional Animal Care and Use Committee of The Medical College of Wisconsin approved. All studies were carried out in accordance with the National Institutes of Health 'Guide for the Care and Use of Experimental Animals'.
Male, Sprague-Dawley rats (Harlan, Madison, WI, USA) weighing 175-225 g were used for these studies. Rats were maintained on a 12:12 light/dark schedule (lights on at 0600 hours) with food and water provided ad libitum. The rats were acclimated to the Biomedical Resource Center of the Medical College of Wisconsin for at least 3 days prior to use in an experiment.
MCA isolation
Rats were deeply anaesthetized by inhalational exposure to isoflurane (Abbott Laboratories, North Chicago, IL, USA) followed by swift decapitation. Brains were removed and the proximal portion of the MCA was dissected and placed into ice-cold, physiological salt solution containing (mM): NaCl (119); KCl (4.9); CaCl 2 (1.6); MgSO 4 (1.17); glucose (5.5); NaHCO 3 (24); NaH 2 PO 4 (1.18); HEPES (5.8) and EDTA (0.026).
MCA vascular reactivity MCA were cleaned of adhering fat and connective tissue and the endothelium was removed by the intraluminal introduction of an air bolus. Endothelium removal was verified by the complete elimination of the vasodilator response to acetylcholine. The MCA were cannulated using tapered glass micropipettes that were fixed within a Lucite perfusion and superfusion chamber as described previously (Gauthier-Rein et al., 1997) . Arteries were maintained at a perfusion pressure of 60 mm Hg; all solutions were equilibrated with 21% O 2 , 5% CO 2 and 74% N 2 . This gas mixture resulted in a pH of 7.4 and pO 2 of 140 mm Hg. Internal diameters were obtained using a Nikon SMZ-800 inverted microscope coupled to a Spot RT camera (Diagnostic Instruments, Sterling Heights, MI, USA); images were captured and analysed using the Spot/ Metaview acquisition and analysis software. Diameters were determined when the vessel reached equilibrium and were calculated as the mean of 12 measurements made along the length of the vessel. At the end of each experiment, the artery was perfused and superfused with Ca 2 þ -free buffer that also contained 1 mM nimodipine to determine the maximum vasodilatory capacity for that preparation. In the experiments investigating the vasodilatory effects of the cannabinoid agonists, the vessels were preconstricted with 1 mM 5-HT and the cannabinoid agonists were added serially. The effects of inhibitors and receptor blockers in single concentration studies were assessed using unpaired Student's t-tests. The effects of the inhibitors on the constrictor responses to U-46619 were determined using two-way analyses of variance, with the concentration of U-46619 as one factor and the presence of inhibitor as the second factor.
Materials
Buffers and salts were purchased from Sigma Chemical Company (St. Louis, MO, USA). U-46619, URB597, URB754, AM1172 and 2-AG were purchased from Cayman Chemical Company (Ann Arbor, MI, USA). Win 55212-2 was purchased from Sigma Chemical Company; AEA and VDM11 were purchased from Tocris Cookson (Ellisville, MO, USA); and rimonabant was obtained from the National Institute on Drug Abuse Drug Inventory Supply Program. 3-(Decylthio)-1,1,1-trifluropropan-2-one (DETFP) was synthesized using previously described methods (Wheelock et al., 2001; Wadkins et al., 2007) .
Results
Exogenously added 2-AG produces modest cerebrovasodilatation
In agreement with previous studies (Gebremedhin et al., 1999; Rademacher et al., 2005) , incubation of 5-HT-constricted, endothelium-denuded rat MCA with the CB receptor agonist Win 55212-2 resulted in significant vasodilatation ( Figure 1 ). The EC 50 value for Win 55212-2 was 33 nM (95% confidence interval: 28-38 nM) and the E max is 37% (36-39%) of the increase in diameter produced by nimodipine/Ca 2 þ -buffer. While 2-AG also produced significant dilatation of the MCA at nanomolar concentrations, the E max for 2-AG was only 10.5% (10.4-10.5%) of the maximal dilatation. To examine the question of the efficacy of 2-AG, we determined whether it can also act as an antagonist. A fully efficacious concentration of Win 55212-2 (1 mM) produced approximately 25% of the maximum diameter; the combination of 1 mM 2-AG and 1 mM Win 55212-2 was not significantly different from that produced by Win 55212-2 alone (Supplementary Figure 1) , indicating that 2-AG is not acting as a partial agonist/antagonist. The vasodilatation produced by 100 nM 2-AG was significantly reduced in the presence of the selective CB 1 receptor antagonist, rimonabant (1 mM) ( Figure 2a ).
Cerebrovasodilatation produced by 2-AG is enhanced by inhibitors of its catabolism
DETFP is a nonselective inhibitor of mammalian carboxylesterases (Wheelock et al., 2001; Wadkins et al., 2007) and is also a potent inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL) (CJ Hillard, unpublished data). All of these enzymes can hydrolyse 2-AG. Coincubation of the MCA with DETFP (10 mM) produced a large increase in the vasodilatory efficacy of 2-AG (Figures 2a  and b) . The EC 50 value for 2-AG was not changed significantly in the presence of DETFP. DETFP also increased the efficacy of AEA to produce vasodilatation of the MCA (Figure 2c ), but DETFP had no effect on the vasodilatation produced by 30 nM Win 55212-2 (2273% in the presence of dimethyl sulphoxide vehicle and 2371% in the presence of 10 mM DETFP). The vasodilatation produced by 2-AG in the presence of DETFP was significantly reduced, but not completely inhibited, by coincubation with 1 mM rimonabant ( Figure 2a) . We examined the effects of several other inhibitors of endocannabinoid inactivation on the vasodilatory effects of 2-AG (Figure 3) . The FAAH inhibitor, URB597 (1 mM) produced a significant increase in the maximal dilation produced by 2-AG; however, this inhibitor was not as effective as DETFP. URB754 (10 mM) increased the per cent maximal dilatation in response to 2-AG to greater than 40%, which is comparable to the effect of DETFP. Two inhibitors of cellular accumulation of anandamide, AM1172 (Fegley et al., 2004) and VDM11 (De Petrocellis et al., 2000) , did not affect 2-AG-mediated vasodilatation when added 5-10 min prior to the addition of 2-AG. Since VDM-11 is also a substrate for FAAH, we examined the effect of simultaneous addition of VDM-11 and 2-AG. VDM-11 produced a small, but These data indicate that 2-AG is hydrolysed by the MCA preparation to arachidonic acid. We have examined the effects of the same concentration range of arachidonic acid to explore the contribution of this metabolite to the effects of exogenous 2-AG. Arachidonic acid did not produce a significant vasodilatation of the 5-HT-constricted MCA (Supplementary Figure 2a) . However, arachidonic acid produced a concentration-related decrease in MCA diameter; the E max obtained was 13% (12.5-14%) and the EC 50 value was 4.0 nM (2.8-6.0 nM) (Supplementary Figure 2b) .
U-46616 cerebrovasoconstriction is blunted by inhibitors of 2-AG catabolism U-46619 produced concentration-dependent constriction of perfused, pressurized and endothelium-denuded MCA (Figure 4) . The EC 50 values for U-46619 varied between 11 and 28 nM and E max values were between 30 and 65% of predrug MCA diameter (Table 1) . Two-way analyses of variance were used to determine whether the presence of inhibitor significantly altered the response of the MCA to U-46619. Addition of dimethyl sulphoxide vehicle to the bath (in the amount used to deliver each of the inhibitors) did not affect the response to U-46619 (Table 1) . Three of the inhibitors studied produced significant effects on the U-46619 contractile effect: DETFP, URB754 and VDM11. DETFP (10 mM) and URB754 (10 mM) produced significant increases in the EC 50 value for U-46619 (Figures 4a and b, Table 1 ). Both compounds also reduced the E max values for U-46619, although this change was significant only for URB754. 2-AG was added alone and the per cent maximal dilation determined; after washing and return of the diameter to resting levels, the inhibitor was added (10 mM) for 5-10 min followed by the addition of 100 nM 2-AG. Each bar is the mean of three determinations; vertical lines represent s.e.m. *A significant difference between the groups indicated with Po0.05; ***A significant difference between the groups indicated with Po0.005. 2-AG, 2-arachidonoylglycerol; MCA, middle cerebral artery.
2-AG and cerebrovasodilatation CJ Hillard et al
Two-way analyses of variance indicated that VDM11 also had a significant effect on the response to U-46619; however, VDM11 did not significantly affect the EC 50 for U-46619 as the 95% confidence intervals for the composite EC 50 values in the absence and presence of VDM11 were overlapping ( Figure 4c and Table 1 ). Neither the FAAH inhibitor, URB597, nor the anandamide accumulation inhibitor, AM1172, affected the contractile response to U-46619 in rat MCA (Table 1) .
Discussion and conclusions
These data support and extend our previous observations that CB 1 receptor agonists are potent and efficacious dilators of the rat MCA (Gebremedhin et al., 1999; Rademacher et al.,
2005
). These results demonstrate that the isolated MCA expresses the enzymatic machinery for the efficient degradation of 2-AG. Finally, these findings provide further support for the hypothesis that activation of thromboxane receptors in the MCA mobilizes the endocannabinoids and that these lipid modulators act via CB 1 receptor activation to dampen thromboxane-mediated vasoconstriction. These data suggest that a function of endocannabinoid/CB 1 receptor signalling in the MCA is to prevent excessive vasoconstriction during thrombosis. These studies were carried out with the endothelium removed from the MCA. The endothelial cells of the MCA express the CB 1 cannabinoid receptor (Chen et al., 2000; Rademacher et al., 2005) and FAAH and are likely important contributors to the overall effects of endogenous and exogenous endocannabinoids. In our Figure 4 Effects of inhibitors of 2-AG catabolism on the constrictor response to U-46619. Rat MCA were denuded and serial concentrations of U-46619 were added in the presence of DMSO (control). After washout and re-equilibration, the inhibitors were added and the U-46619 concentration-response curve was re-determined. The inhibitors used were: DETFP (a; 10 mM; n ¼ 4); URB754 (b; 10 mM; n ¼ 4) and VDM11 (c; 10 mM; n ¼ 5). 2-AG, 2-arachidonoylglycerol; DETFP, 3-(decylthio)-1,1,1-trifluropropan-2-one; DMSO, dimethyl sulphoxide; MCA, middle cerebral artery. Units are per cent decrease in diameter. b P-values were determined using 2-way ANOVA with U-46619 concentration and the presence of inhibitor as the two factors; in all cases the effect of U-46617 concentration was significant at Po0.0001 and there were no significant interactions. The P-values for the 'presence of inhibitor' factor are shown.
c DMSO equivalent to that added with each inhibitor.
2-AG and cerebrovasodilatation CJ Hillard et al earlier study , we found that the effect of U-46619 on endocannabinoid content was not affected by the presence of the endothelium, suggesting that the vascular smooth muscle is the primary site of endocannabinoid production in the MCA. However, the endothelium could play a role in the catabolism of the endocannabinoids. In addition, the endothelial cells are likely to exert a modulatory influence on the vasodilatatory effects of the endocannabinoids, if not directly via CB 1 receptor activation, then indirectly via the release of nonendocannabinoid mediators of vascular tone. Therefore, while the present studies demonstrate that the vascular smooth muscle catabolizes the endocannabinoids, it is likely that the MCA endothelial cells also contribute to this process. The EC 50 value for the cannabinoid receptor agonist, Win 55212-2, to produce vasodilatation of the MCA is 30 nM, which correlates remarkably well with the IC 50 value for the same agonist to inhibit the opening of L-type calcium channels in isolated cat arterial smooth muscle cells (Gebremedhin et al., 1999) . In previous studies, we have shown that the vasodilatation produced by Win 55212-2 was inhibited by coincubation with the CB 1 receptor-selective antagonist, rimonabant (SR141716) (Gebremedhin et al., 1999) . We have extended those findings in this study and demonstrate that two endocannabinoids 2-AG and AEA also vasodilate rat MCA at nanomolar concentrations. However, E max for 2-AG was less than one-quarter of the E max for Win 55212-2 in the same assay. This result is inconsistent with the high efficacy of 2-AG in assays of CB 1 receptor-induced GDP/GTP exchange (Hillard, 2000a) and calcium mobilization (Sugiura et al., 1997) , where 2-AG acts as a full agonist of the CB 1 receptor. Interestingly, the E max for 2-AG was also significantly less than the E max for AEA, a ligand that generally acts as a partial agonist of the CB 1 receptor (Kearn et al., 1999) . Since 2-AG did not reduce the efficacy of a maximally effective concentration of Win 55212-2, it is not likely to be acting as a partial agonist of the CB 1 receptor in the MCA.
A more likely explanation for these data is that exogenously added 2-AG is rapidly inactivated by the isolated MCA which results in a reduction in its efficacy. This hypothesis is supported by recent data from Ho and Randall (2007) demonstrating significant metabolism of the endocannabinoids in small mesenteric arteries. However, our data suggest that the low efficacy of 2-AG results from more than just catabolic inactivation. If this were the case, then high concentrations of 2-AG should saturate the catabolic processes and result in higher efficacy. If anything, very high concentrations of 2-AG either had no effect or induced vasoconstriction (data not shown). Instead, it is likely that 2-AG acts as both an agonist of the CB 1 receptor and as a precursor for arachidonic acid, which, in turn, is converted to vasoconstrictor eicosanoids, such as 20-hydroxyeicosatetraenoic acid (Roman et al., 2006) . In fact, we have found that arachidonic acid produces significant vasoconstriction of the endothelium-denuded MCA, but does not produce significant vasodilatation. Therefore, we hypothesize that as greater concentrations of 2-AG are added and hydrolysed to arachidonic acid, greater amounts of an arachidonatederived vasoconstrictor are produced which acts as a functional antagonist of intact 2-AG.
A primary mechanism of 2-AG inactivation is hydrolysis to glycerol and arachidonic acid, since neither of these metabolites bind to the CB 1 receptor (Bisogno et al., 1997; Dinh et al., 2002) . 2-AG hydrolysis can be accomplished through several enzymatic pathways, including MGL (Dinh et al., 2004) , FAAH (Di Marzo et al., 1999b) , and other uncharacterized esterases (Nithipatikom et al., 2005) . In the brain, the primary mechanism for the catabolism of AEA is hydrolysis by FAAH. In fact, there is no detectable AEA hydrolysis in membranes prepared from FAAH À/À mice . A series of trifluoromethylketone-containing compounds have been developed and found to act as a tight binding, reversible and potent (nM) inhibitors of mammalian carboxylesterases (Wheelock et al., 2001; Wadkins et al., 2007) . Nithipatikom et al. (2005) have reported that members of this series are potent inhibitors of exogenous and endogenous 2-AG inactivation in cells. We have studied these compounds in vitro and found that the decyl derivative, DETFP, is a potent inhibitor of FAAH and the hydrolysis of 2-acylglycerols by brain cytosolic preparations with IC 50 values of 5 and 800 nM, respectively.
Our initial approach to examine the role of catabolism in the low efficacy of 2-AG to vasodilate the MCA was to use the trifluoromethylketone series of inhibitors, since they inhibit all of the known pathways of 2-AG metabolism. The coincubation of the MCA with DETFP resulted in a large increase in the E max for 2-AG to produce vasodilatation. These data are consistent with the hypothesis that the majority of exogenously added 2-AG is hydrolysed by the MCA preparation and indicate that DETFP inhibits that metabolism. DETFP did not affect the EC 50 value for 2-AG, suggesting that the pool of 2-AG that is not metabolized acts via the CB 1 receptor to produce vasodilatation. This conclusion is supported by the complete blockade by rimonabant of 2-AG vasodilatation in the absence of DETFP. DETFP also increased the E max for AEA in the MCA. Since AEA is not a substrate for MGL (Goparaju et al., 1999) and does not contain an ester moiety, it is possible that the effect of DETFP on AEA E max is via inhibition of FAAH. This hypothesis is in agreement with our finding that DETFP is a very potent inhibitor of FAAH (IC 50 value of 5 nM). Finally, DETFP did not affect Win 55212-2-mediated vasodilatation of the MCA, which is provides evidence that DETFP does not affect the signalling cascade initiated by CB 1 receptor activation. Interestingly, the CB 1 receptor antagonist, rimonabant, did not completely inhibit the vasodilatory effect of 2-AG in the presence of DETFP. These data suggest that, at high concentrations, 2-AG either acts itself via a non-CB 1 receptor mechanism to produce vasodilatation or is converted to a metabolite that vasodilates via another mechanism. With regard to the second of these possibilities, we would expect DETFP to completely inhibit 2-AG conversion to arachidonic acid at this concentration, so it is not likely that arachidonic acid is an intermediate in the production of active metabolites.
We have identified two other inhibitors that also increase the E max for 2-AG to produce vasodilatation: URB754 and URB597. We have also examined the effects of URB754 on the ability of 2-AG to produce vasodilatation of the MCA. URB754 was originally described as an inhibitor of MGL (Makara et al., 2005) , although the inhibition was subsequently attributed to a contaminant (Makara et al., 2007) . Others report that the inhibitor has no effect on the hydrolysis or signalling capacity of 2-AG in brain (Saario et al., 2006; Vandevoorde et al., 2007) . In our assay of 2-acylglycerol hydrolysis by brain cytosol (Rademacher et al., 2007) , URB754 is an effective although not very potent inhibitor, exhibiting an IC 50 value of 42 mM and inhibiting approximately 90% of 2-oleoylglycerol hydrolysis. Based upon its relatively potent effect in the current study (URB754 produced a threefold increase in the maximal dilation by 2-AG at a concentration of 10 mM), it is possible that a primary mechanism for the hydrolysis of 2-AG in the MCA is an as-yet uncharacterized hydrolase that can be inhibited by URB754 and DETFP. While further studies are needed to characterize the second pathway, the relatively high potency of URB754 compared to its potency to inhibit MGL in brain suggests that the target of URB754 is not MGL. It is our current hypothesis that URB754 and DETFP, which have very different structures, inhibit a common, as yet uncharacterized, hydrolase.
URB597 is an inhibitor of FAAH that has very little effect on 2-acylglycerol hydrolysis in brain cytosol (Saario et al., 2004) or in membranes from FAAH À/À mice (CJ Hillard, unpublished data). Although neither pharmacologic inhibition nor complete ablation of FAAH affect total brain 2-AG levels , there is clear evidence from in vitro studies that 2-AG is a substrate for FAAH (Di Marzo et al., 1999a) . Therefore, the URB597 data could reflect hydrolysis of 2-AG by FAAH in the MCA. However, two other inhibitors of FAAH, AM1172 (CJ Hillard, unpublished data) and VDM11 (Vandevoorde and Fowler, 2005) did not significantly enhance 2-AG vasodilatory efficacy. Therefore, it is possible that the effect of URB597 on 2-AG is not due to inhibition of FAAH. We have also examined the effects of two inhibitors of AEA accumulation in neurons, AM1174 (Fegley et al., 2004) and VDM11 (De Petrocellis et al., 2000) on 2-AG efficacy. Neither of these inhibitors produced a significant effect on 2-AG-mediated vasodilatation, which indicates that re-uptake processes do not affect the ability of 2-AG to reach its metabolic enzymes in the MCA. In the second set of studies, we examined the effects of the inhibitors on the response of the MCA to the vasoconstrictor, U-46619. Our earlier studies demonstrated that U-44619 increases the MCA contents of both 2-AG and AEA and that the endocannabinoids oppose U-46619-induced vasoconstriction via activation of the CB 1 receptor . In particular, we found that rimonabant and AM251 enhanced U-46619 constrictions. A prediction of the hypothesis derived from these earlier studies is that inhibition of endocannabinoid hydrolysis should reduce U-46619 vasoconstrictions. Our results are consistent with this prediction: both DETFP and URB754 produced a significant rightward shift in the U-46619 constriction curve. This shift was reflected in an increase in the EC 50 value for U-46619. Although URB597 potentiated the vasodilatory effect of exogenous 2-AG, it did not affect the response to U-46619.
These data indicate that although FAAH is present in the MCA, it does not play a significant role in the regulation of endocannabinoid that is synthesized in response to U-44619. Interestingly, VDM11, an uptake inhibitor that also inhibits FAAH and MGL (Vandevoorde and Fowler, 2005) , also produced a significant change in the U-44619 response as revealed by two-way analyses of variance. However, although the EC 50 for U-46619 was increased in the presence of VDM11, it was not significantly different from the control value. The significance of these data is not clear at present; however, the lack of effect of either AM1172 or URB597 suggests that it is the ability of VDM11 to inhibit 2-oleoylglycerol hydrolysis that is responsible for its effect.
These findings support the hypothesis that vascular smooth muscle cells of the cerebral circulation use endocannabinoid signalling to produce local changes in vessel tone. In addition to the expression of the CB 1 cannabinoid receptor (Gebremedhin et al., 1999) and processes for the synthesis of the endocannabinoids , the current studies demonstrate that the MCA also has intrinsic processes for the catabolism of the endocannabinoids. Furthermore, because thromboxane A 2 is released by activated platelets and contributes to cerebral vasospasm (von Holst et al., 1982) , our data suggest that the endocannabinoid signalling system plays a very important and significant role in the negative regulation of vasoconstriction during thrombosis. As such, inhibitors of endocannabinoid inactivation could represent a novel class of agents for the treatment of thrombotic disorders, particularly those occurring within the cerebral circulation.
